Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse til evaluering af opretholdelsen af ​​effektivitet ved overgang fra anti-klynge af differentierede 20 (CD20) terapi til Ublituximab (ENHANCE)

22. oktober 2026 opdateret af: TG Therapeutics, Inc.

Evaluering af opretholdelse af effektivitet ved overgang fra anti-CD20-terapi til Ublituximab

The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

Studieoversigt

Status

Rekruttering

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

800

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35209
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Cullman, Alabama, Forenede Stater, 35058
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • California
      • Orange, California, Forenede Stater, 92697
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Colorado
      • Fort Collins, Colorado, Forenede Stater, 80528
        • Rekruttering
        • TG Investigational Site
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20007
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Florida
      • Tampa, Florida, Forenede Stater, 33612
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30309
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Savannah, Georgia, Forenede Stater, 31406
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46256
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Kansas
      • Overland Park, Kansas, Forenede Stater, 66212
        • Afsluttet
        • TG Therapeutics Investigational Trial Site
      • Overland Park, Kansas, Forenede Stater, 66205
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Maryland
      • Lutherville, Maryland, Forenede Stater, 21093
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 70809
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Boston, Massachusetts, Forenede Stater, 00002
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Foxborough, Massachusetts, Forenede Stater, 02035
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • North Worcester, Massachusetts, Forenede Stater, 01655
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Wellesley, Massachusetts, Forenede Stater, 02481
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Michigan
      • Farmington, Michigan, Forenede Stater, 48334
        • Rekruttering
        • TG Investigational Site
    • Minnesota
      • Golden Valley, Minnesota, Forenede Stater, 55422
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Plymouth, Minnesota, Forenede Stater, 55446
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63131
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • New York
      • New York, New York, Forenede Stater, 10025
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • New York, New York, Forenede Stater, 11021
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Rekruttering
        • TG Therapeutics Investigational Trial SiteCharlotte
      • Raleigh, North Carolina, Forenede Stater, 27607
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45212
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Dayton, Ohio, Forenede Stater, 45417
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • South Carolina
      • Greenville, South Carolina, Forenede Stater, 29605
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Tennessee
      • Knoxville, Tennessee, Forenede Stater, 37922
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Afsluttet
        • TG Therapeutics Investigational Trial Site
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84103
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Virginia
      • Vienna, Virginia, Forenede Stater, 22182
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Washington
      • Kirkland, Washington, Forenede Stater, 98034
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Seattle, Washington, Forenede Stater, 98109
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Spokane, Washington, Forenede Stater, 99208
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Bydgoszcz, Polen, 85-796
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Katowice, Polen, 40-555
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Kielce, Polen, 25-726
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Krakow, Polen, 31-826
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Lodz, Polen, 90-324
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Olsztyn, Polen, 10-561
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Poznan, Polen, 61-583
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Warsaw, Polen, 04-141
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Zabrze, Polen
        • Rekruttering
        • TG Therapeutics Investigational Trial Site
      • Żory, Polen, 44-240
        • Rekruttering
        • TG Therapeutics Investigational Trial Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosis of RMS (2017 Revised McDonald criteria).

  • Participants must meet one of the following prior treatment definitions:

    1. Participants naïve to treatment.
    2. Participants previously treated with a disease modifying therapy (DMT) who have discontinued treatment prior to consent and meet the washout requirements.
  • Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.

  • Neurologically stable for > 30 days prior to first dose of ublituximab.

  • Female participants of childbearing potential must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 6 months after the last dose of ublituximab.

  • Part C: participants currently treated with an anti-CD20 agent for at least 6 months and meet the washout requirements prior to W1D1.

  • Part C: Discontinuation of current anti-CD20 must be due to suboptimal experience

Exclusion Criteria:

  • History of any serious 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.
  • Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).
  • Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
  • Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).
  • Previous serious opportunistic or atypical infection.
  • Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
  • History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).
  • Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.
  • Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.
  • Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.
  • Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).

Note: Other Inclusion/Exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part A: Ublituximab

Participants will receive a modified regimen of ublituximab including infusions on Day 1 of Week 1 (W1D1), Day 15, if applicable, and ublituximab 450 milligrams (mg) infusion at Week 24.

With Protocol Version 6.0, enrollment in Part A was closed.

Administered as an intravenous (IV) infusion.

Andre navne:
  • TG-1101
  • BRIUMVI
Eksperimentel: Part B: Ublituximab /Placebo (Treatment Arm A)

Participants will receive 600 mg of ublituximab on W1D1 followed by a placebo infusion on Day 15 and 450 mg ublituximab infusion at Week 24.

With Protocol Version 7.0, enrollment in Part B will be closed.

IV infusion

Administered as an intravenous (IV) infusion.

Andre navne:
  • TG-1101
  • BRIUMVI
Eksperimentel: Part B: Ublituximab (Treatment Arm B)

Participants will receive 150 mg of ublituximab on W1D1 followed by 450 mg on Day 15 and at Week 24.

With Protocol Version 7.0, enrollment in Part B will be closed.

Administered as an intravenous (IV) infusion.

Andre navne:
  • TG-1101
  • BRIUMVI
Eksperimentel: Part C: Ublituximab (Treatment Arm C)

Participants will receive 150 mg of ublituximab on W1D1, followed by 450 mg on Day 15 and at Week 24.

Administered as an intravenous (IV) infusion.

Andre navne:
  • TG-1101
  • BRIUMVI

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Del B: Areal under kurven i de første 16 uger (AUC0-W16) for ublituximab
Tidsramme: Før dosering og på flere tidspunkter op til uge 16
Før dosering og på flere tidspunkter op til uge 16
Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48
Tidsramme: Baseline up to Week 48

The Gd-enhancing T1 lesions will be evaluated using magnetic resonance imaging (MRI) technique.

Baseline up to Week 48

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Parts A: Percentage of Participants Free of T1 Gd-Enhancing Lesions
Tidsramme: Week 48

The Gd-enhancing T1 lesions will be evaluated using MRI technique.

Week 48
Parts A and B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs)
Tidsramme: Up to Week 48

IRRs are defined as infusion related adverse events (AEs) that occur within one day of an infusion and resolve within 7 days. IRRs will be reported by investigator.

Up to Week 48
Parts A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores
Tidsramme: Part A: Baseline, Week 24 and Week 48

The TSQM-9 is a 9-item questionnaire with 3 domains: Satisfaction, convenience, and effectiveness.

Part A: Baseline, Week 24 and Week 48

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. juni 2023

Primær færdiggørelse (Anslået)

21. januar 2027

Studieafslutning (Anslået)

21. januar 2027

Datoer for studieregistrering

Først indsendt

18. maj 2023

Først indsendt, der opfyldte QC-kriterier

18. maj 2023

Først opslået (Faktiske)

26. maj 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • TG1101-RMS401
  • 2024-519284-18-00 (Anden identifikator: EU CT Number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner